

Zelminemab

Cat. No.:	HY-P99509
CAS No.:	2225850-33-7
Target:	Adenylate Cyclase
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Zelminemab (AMG-301) is a humanized monoclonal antibody that inhibits PACAP type I (PAC1) receptor ^[1] .	
In Vivo	Zelminemab (10 mg/kg; i.v.; once) reduces nociceptive neuronal activity in the TCC ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Sprague-Dawley rats, electrical stimulation was performed on the intact dura mater above the middle meningeal artery ^[2] .
	Dosage:	10 mg/kg
	Administration:	i.v.; once
	Result:	Induced an inhibition of stimulus-evoked nociceptive activity in the trigemino-cervical complex (TCC).

REFERENCES

[1]. Eloisa Rubio-Beltrán, et al. PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain. 2018 Aug 7;19(1):64.

[2]. Hoffmann J, et al. PAC-1 receptor antibody modulates nociceptive trigeminal activity in rat. Cephalalgia. 2016;36(1S):141-141.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA